4 results on '"Jerzewski K"'
Search Results
2. Black box warning: is ketorolac safe for use after cardiac surgery?
- Author
-
Oliveri L, Jerzewski K, and Kulik A
- Subjects
- Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Cardiac Surgical Procedures mortality, Cohort Studies, Coronary Artery Bypass, Creatinine blood, Databases, Factual, Dialysis, Female, Humans, Ketorolac therapeutic use, Kidney Function Tests, Logistic Models, Male, Middle Aged, Postoperative Hemorrhage epidemiology, Postoperative Hemorrhage therapy, Reoperation, Retrospective Studies, Risk Assessment, Treatment Outcome, Anti-Inflammatory Agents, Non-Steroidal adverse effects, Cardiac Surgical Procedures methods, Ketorolac adverse effects, Pain, Postoperative drug therapy
- Abstract
Objective: In 2005, after the identification of cardiovascular safety concerns with the use of nonsteroidal anti-inflammatory drugs (NSAIDs), the FDA issued a black box warning recommending against the use of NSAIDs following cardiac surgery. The goal of this study was to assess the postoperative safety of ketorolac, an intravenously administered NSAID, after cardiac surgery., Design: Retrospective observational study., Setting: Single center, regional hospital., Participants: A total of 1,309 cardiac surgical patients (78.1% coronary bypass, 28.0% valve) treated between 2006 and 2012., Interventions: A total of 488 of these patients received ketorolac for postoperative analgesia within 72 hours of surgery., Measurement and Main Results: Ketorolac-treated patients were younger, had better preoperative renal function, and underwent less complex operations compared with non-ketorolac patients. Ketorolac was administered, on average, 8.7 hours after surgery (mean doses: 3.1). Postoperative outcomes for ketorolac-treated patients were similar to those expected using Society of Thoracic Surgery database risk-adjusted outcomes. In unadjusted analysis, patients who received ketorolac had similar or better postoperative outcomes compared with patients who did not receive ketorolac, including gastrointestinal bleeding (1.2% v 1.3%; p = 1.0), renal failure requiring dialysis (0.4% v 3.0%; p = 0.001), perioperative myocardial infarction (1.0% v 0.6%; p = 0.51), stroke or transient ischemic attack (1.0% v 1.7%; p = 0.47), and death (0.4% v 5.8%; p<0.0001). With adjustment in a multivariate model, treatment with ketorolac was not a predictor for adverse outcome in this cohort (odds ratio: 0.72; p = 0.23)., Conclusions: Ketorolac appears to be well-tolerated for use when administered selectively after cardiac surgery. Although a black box warning exists, the data highlights the need for further research regarding its perioperative administration., (Copyright © 2014 Elsevier Inc. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
3. Does high-density lipoprotein influence the development of saphenous vein graft disease after coronary bypass surgery?: exploratory analysis from the CASCADE trial.
- Author
-
Jerzewski K, Ruel M, Voisine P, Le May MR, and Kulik A
- Subjects
- Aged, Angiography, Clopidogrel, Female, Follow-Up Studies, Humans, Hyperplasia, Male, Middle Aged, Postoperative Period, Risk Assessment, Saphenous Vein pathology, Ticlopidine therapeutic use, Tunica Intima pathology, Coronary Artery Bypass adverse effects, Graft Occlusion, Vascular etiology, Lipoproteins, HDL blood, Platelet Aggregation Inhibitors therapeutic use, Saphenous Vein transplantation, Ticlopidine analogs & derivatives
- Abstract
Background: Low levels of high-density lipoprotein (HDL) purportedly increase the risk after coronary bypass surgery. This may relate to the development of saphenous vein graft (SVG) disease early postoperatively, but this premise has never been evaluated in the context of a prospective trial., Methods: The CASCADE Trial was a multi-center study of 113 patients evaluating the use of postoperative clopidogrel. Patients received standard lipid management after surgery (96% statins). At 12 months, angiography and intravascular ultrasound was performed to assess SVG occlusion and intimal hyperplasia, respectively. In this exploratory analysis, we evaluated the influence of HDL levels on the development of SVG disease at 12 months, using the established cut-off of <40 mg/dL suggesting increased risk., Results: While HDL levels increased over the time-period of the trial (P < 0.0001), 51.1% of patients had HDL levels <40 mg/dL 12 months after surgery. Slightly more SVG occlusions occurred amongst patients with HDL levels <40 mg/dL (6.8%), compared to patients with HDL levels >40 mg/dL (4.0%, P = 0.5). With multivariate adjustment, HDL level <40 mg/dL was associated with a trend towards more SVG occlusions (odds ratio: 3.2; P = 0.12). Lower HDL level was also associated with more intimal hyperplasia on ultrasound at 12 months (P = 0.10). Patients who had HDL levels >60 mg/dL had the least amount of intimal hyperplasia, significantly less than the remainder of the cohort (P = 0.01)., Conclusions: Within this population, lower HDL levels were associated with trends towards more graft occlusions and more vein intimal hyperplasia. Modulation of postoperative HDL levels may represent a valuable future strategy for the reduction of SVG disease.
- Published
- 2013
- Full Text
- View/download PDF
4. Sexual dimorphism in development of kidney damage in aging Fischer-344 rats.
- Author
-
Sasser JM, Akinsiku O, Moningka NC, Jerzewski K, Baylis C, LeBlanc AJ, Kang LS, Sindler AL, and Muller-Delp JM
- Subjects
- Age Factors, Animals, Disease Models, Animal, Female, Male, Nitric Oxide metabolism, Rats, Rats, Inbred F344, Aging metabolism, Kidney Cortex metabolism, Kidney Glomerulus metabolism, Nitric Oxide Synthase Type I metabolism, Nitric Oxide Synthase Type III metabolism, Sex Characteristics
- Abstract
Background: Aging kidneys exhibit slowly developing injury and women are usually protected compared with men, in association with maintained renal nitric oxide., Objectives: Our purpose was to test 2 hypotheses: (1) that aging intact Fischer-344 (F344) female rats exhibit less glomerular damage than similarly aged males, and (2) that loss of female ovarian hormones would lead to greater structural injury and dysregulation of the nitric oxide synthase (NOS) system in aging F344 rat kidneys., Methods: We compared renal injury in F344 rats in intact, ovariectomized, and ovariectomized with estrogen replaced young (6 month) and old (24 month) female rats with young and old intact male rats and measured renal protein abundance of NOS isoforms and oxidative stress., Results: There was no difference in age-dependent glomerular damage between young or old intact male and female F344 rats, and neither ovariectomy nor estrogen replacement affected renal injury; however, tubulointerstitial injury was greater in old males than in old females. These data suggest that ovarian hormones do not influence these aspects of kidney aging in F344 rats and that the greater tubulointerstitial injury is caused by male sex. Old males had greater kidney cortex NOS3 abundance than females, and NOS1 abundance (alpha and beta isoforms) was increased in old males compared with both young males and old females. NOS abundance was preserved with age in intact females, ovariectomy did not reduce NOS1 or NOS3 protein abundance, and estrogen replacement did not uniformly elevate NOS proteins, suggesting that estrogens are not primary regulators of renal NOS abundance in this strain. Nicotinamide adenine dinucleotide phosphate oxidase-dependent superoxide production and nitrotyrosine immunoreactivity were increased in aging male rat kidneys compared with females, which could compromise renal nitric oxide production and/or bioavailability., Conclusions: The kidney damage expressed in aging F344 rats is fairly mild and is not related to loss of renal cortex NOS3 or NOS1 alpha., (Copyright © 2012 Elsevier HS Journals, Inc. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.